Lisa Urquhart - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Lisa Urquhart's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Lisa Urquhart
Verified
Pharma and Biotech Editor/Writer, Freelance
Beats
Artificial Intelligence, FinTech, NFT Blockchain, Metaverse, CybersecurityAI, Politics, Future Work Future, Cryptocurrency, LegalTech DAO
Equities
Content
F2G seeks second bite of the cherry with $100 million round as novel antifungal pipeline remains thin
By Lisa Urquhart Verified| The Pharma Letter Verified F2G’s September $100m funding round provides the company with crucial funds to renavigate approval of its lead drug, olorofim. The substantial financing also highlights the paucity of novel antifungal products in the clinic. Olorofim is an orotomides, one of the few novel antifungal classes developed in the past 20 years. Olorofim is also the only antifungal project to be awarded a breakthrough therapy designation for multiple indications by the FDA.
By Lisa Urquhart Verified| The Pharma Letter Verified Aardvark Therapeutics might not have scored the biggest venture haul in May, but its $85 million Series C round will further strengthen rumors that the California-based company is gearing up for an initial public offering (IPO) this summer, which could come as soon as late July.
F2G seeks second bite of the cherry with $100 million round as novel antifungal pipeline remains thin
By Lisa Urquhart Verified| The Pharma Letter Verified F2G’s September $100m funding round provides the company with crucial funds to renavigate approval of its lead drug, olorofim. The substantial financing also highlights the paucity of novel antifungal products in the clinic. Olorofim is an orotomides, one of the few novel antifungal classes developed in the past 20 years. Olorofim is also the only antifungal project to be awarded a breakthrough therapy designation for multiple indications by the FDA.
Company Info
Freelance
Freelancer.com is the largest freelancing and crowdsourcing marketplace in the world, connecting over 81 million employers and freelancers across more than 247 countries. Founded in 2009 and based in Sydney, Australia, the platform allows employers to post jobs while freelancers can bid on these projects. It is publicly traded on the Australian Securities Exchange under the ticker ASX:FLN. The platform supports a variety of work categories, including software development, writing, design, and marketing. Freelancer.com also offers contests for creative work, where employers can award prize money to winning entries. Users can choose from different membership plans, including free and paid subscriptions, which provide various benefits. The mobile app enhances project management and communication for users on the go. With a diverse customer base that includes individuals, small businesses, and large enterprises, Freelancer.com plays a significant role in the global online economy.
De Pere, Wisconsin, United States